SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kimia Biosciences - Quaterly Results

14 Feb 2024 Evaluate
A decrease in the sales to Rs. 261.45 millions was observed for the quarter ended December 2023. The sales stood at Rs. 288.02 millions during the similar quarter previous year.The Net Loss for the quarter ended December 2023 is Rs. -19.52 millions as compared to Net Loss of Rs. -34.61 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 improved to -4.71% as compared to -26.89% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 261.45 288.02 -9.23 745.75 1058.53 -29.55 1285.16 1249.01 2.89
Other Income 5.76 2.64 118.18 13.38 8.51 57.23 12.13 9.32 30.15
PBIDT -4.71 -26.89 -82.48 -33.09 12.37 -367.50 -37.63 15.64 -340.60
Interest 13.11 10.49 24.98 37.06 29.84 24.20 42.45 36.41 16.59
PBDT -17.82 -37.38 -52.33 -70.15 -17.47 301.55 -90.56 -20.77 336.01
Depreciation 8.19 8.43 -2.85 24.74 24.64 0.41 33.32 29.41 13.29
PBT -26.01 -45.81 -43.22 -94.89 -42.11 125.34 -123.88 -50.18 146.87
TAX -6.49 -11.20 -42.05 -23.85 -10.22 133.37 -30.36 -13.15 130.87
Deferred Tax -6.49 -11.20 -42.05 -23.85 -10.22 133.37 -30.36 -13.15 130.87
PAT -19.52 -34.61 -43.60 -71.04 -31.89 122.77 -93.52 -37.03 152.55
Equity 47.31 47.31 0.00 47.31 47.31 0.00 47.31 47.31 0.00
PBIDTM(%) -1.80 -9.34 -80.70 -4.44 1.17 -479.69 -2.93 1.25 -333.83

Kimia Biosciences Share Price

38.44 0.76 (2.02%)
17-Apr-2026 12:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.85
Dr. Reddys Lab 1230.00
Cipla 1235.00
Zydus Lifesciences 944.40
Lupin 2307.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×